Skip to main content

Advertisement

SpringerLink
Log in

Predicting Factors of Fistula Healing and Clinical Remission After Infliximab-Based Combined Therapy for Perianal Fistulizing Crohn’s Disease

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Perianal fistulizing Crohn’s disease (PFCD) treatment is based on fistula drainage, antibiotics, immunosuppressant (IS) drugs, and infliximab. Our aim was to study the effectiveness of combination therapy on PFCD and to search for clinical or imaging features associated with the initial complete clinical response and its stability overtime. Patients and methods All patients with PFCD treated in our tertiary center between 2000 and 2005 by infliximab in combination with seton placement and/or IS and evaluated by MRI before treatment were included in the study. Basal clinical and MRI characteristics were recorded. Response to treatment was evaluated after the infliximab induction regiment and at the end of the follow-up. Results Twenty-six patients were included and followed-up for an average 4.9 years. A complex fistula was present in 69% (18/26 patients) of cases and eight (8/26 patients) had an ano-vaginal fistula. After infliximab induction therapy, 13 patients (50%) achieved a complete clinical response. The initial clinical response was significantly associated with the absence of both, active intestinal disease (54% vs. 8%, P = 0.03) and active proctitis (77% vs. 23%, P = 0.01). No initial MRI characteristics were linked to the initial response. In multivariate analysis, only the presence of active proctitis was associated with the lack of response (P = 0.047). At the end of the follow-up, 42% of the patients remained in clinical remission. No clinical characteristics were associated to sustained response when among long-standing responders two exhibited a normal post-treatment MRI. Conclusion An initial complete response of PFCD was observed in half of the patients after combined therapy including infliximab that decreased to 42% later on. Complete healing of fistulas on MRI was possible but unusual. The initial response seemed related to the absence of active intestinal disease, especially in the rectum, when the long-term response could not be predicted by the basal characteristics of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn’s disease. Gastroenterology. 2006;130:650–656. doi:10.1053/j.gastro.2005.12.019.

    Article  PubMed  Google Scholar 

  2. Gower-Rousseau C, Salomez JL, Dupas JL, et al. Incidence of inflammatory bowel disease in northern France (1988–1990). Gut. 1994;35:1433–1438. doi:10.1136/gut.35.10.1433.

    Article  PubMed  CAS  Google Scholar 

  3. Molinie F, Gower-Rousseau C, Yzet T, et al. Opposite evolution in incidence of Crohn’s disease and ulcerative colitis in Northern France (1988–1999). Gut. 2004;53:843–848. doi:10.1136/gut.2003.025346.

    Article  PubMed  CAS  Google Scholar 

  4. Singh B, Mc C, Mortensen NJ, Jewell DP, George B. Perianal Crohn’s disease. Br J Surg. 2004;91:801–814. doi:10.1002/bjs.4613.

    Article  PubMed  CAS  Google Scholar 

  5. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340:1398–1405. doi:10.1056/NEJM199905063401804.

    Article  PubMed  CAS  Google Scholar 

  6. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350:876–885. doi:10.1056/NEJMoa030815.

    Article  PubMed  CAS  Google Scholar 

  7. Ouraghi A, Nieuviarts S, Mougenel JL, et al. Infliximab therapy for Crohn’s disease anoperineal lesions. Gastroenterol Clin Biol. 2001;25:949–956.

    PubMed  CAS  Google Scholar 

  8. Lichtenstein G, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology. 2005;128:862–869. doi:10.1053/j.gastro.2005.01.048.

    Article  PubMed  CAS  Google Scholar 

  9. West RL, van der Woude CJ, Hansen BE, et al. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn’s disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2004;20:1329–1336. doi:10.1111/j.1365-2036.2004.02247.x.

    Article  PubMed  CAS  Google Scholar 

  10. Hyder SA, Travis S, Jewell D, Mortensen N, George B. Fistulating anal Crohn’s disease: results of combined surgical and infliximab treatment. Dis Colon Rectum. 2006;49:1837–1841. doi:10.1007/s10350-006-0656-5.

    Article  PubMed  Google Scholar 

  11. Schwartz DA, Herdman CR. Review article: the medical treatment of Crohn’s perianal fistulas. Aliment Pharmacol Ther. 2004;19:953–967. doi:10.1111/j.1365-2036.2004.01917.x.

    Article  PubMed  CAS  Google Scholar 

  12. Ochsenkuhn T, Goke B, Sackmann M. Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn’s disease. Am J Gastroenterol. 2002;97:2022–2025.

    PubMed  Google Scholar 

  13. Schroder O, Blumenstein A, Schulte-Bockholt A, Stein J. Combining infliximab and methotrexate in fistulizing Crohn’s disease resistant or intolerant to azathioprine. Aliment Pharmacol Ther. 2004;19:295–301. doi:10.1111/j.1365-2036.2004.01850.x.

    Article  PubMed  CAS  Google Scholar 

  14. Markowitz J, Rosa J, Grancher K, Aiges H, Daum F. Long-term 6-mercaptopurine treatment in adolescents with Crohn’s disease. Gastroenterology. 1990;90:1347–1351.

    Google Scholar 

  15. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann Intern Med. 1995;123:132–142.

    PubMed  CAS  Google Scholar 

  16. Topstad DR, Panaccione R, Heine JA, Johnson DRE, MacLean AR, Buie WD. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn’s disease. A single center experience. Dis Colon Rectum. 2003;46:577–583. doi:10.1007/s10350-004-6611-4.

    Article  PubMed  Google Scholar 

  17. Williams JG, Rothenberger DA, Nemer FD, Goldberg SM. Fistula-in ano in Crohn’s disease. Results of aggressive surgical treatment. Dis Colon Rectum. 1991;34:378–384. doi:10.1007/BF02053687.

    Article  PubMed  CAS  Google Scholar 

  18. Ardizzone S, Maconi G, Colombo E, Bollani Sand MG, Bianchi Porro G. Perianal fistulae following infliximab treatment. Clinical and endosonographic outcome. Inflamm Bowel Dis. 2004;10:91–96. doi:10.1097/00054725-200403000-00005.

    Article  PubMed  Google Scholar 

  19. Van Assche G, Vanbeckevoort D, Bielen D, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn’s disease. Am J Gastroenterol. 2003;98:332–339.

    Article  PubMed  Google Scholar 

  20. Loftus EV. Editorial imaging and therapy for perianal Crohn’s disease: on the right track? Am J Gastroenterol. 2004;99:89–90. doi:10.1111/j.1572-0241.2004.04016.x.

    Article  PubMed  Google Scholar 

  21. Parsi MA, Achkar JP, Richardson S, et al. Predictors of response to infliximab in patients with Crohn’s disease. Gastroenterology. 2002;123:707–713. doi:10.1053/gast.2002.35390.

    Article  PubMed  CAS  Google Scholar 

  22. Parsi MA, Lashner BA, Achkar JP, Connor JT, Brzezinski A. Type of fistula determines responses to infliximab in patients with fistulous Crohn’s disease. Am J Gastroenterol. 2004;99:445–449. doi:10.1111/j.1572-0241.2004.04083.x.

    Article  PubMed  CAS  Google Scholar 

  23. Vermeire S, Louis E, Carbonez A, et al. Demographic and clinical parameters influencing the short-term outcome of anti-TNF necrosis factor (infliximab) treatment on Crohn’s disease. Am J Gastroenterol. 2002;97:2357–2363. doi:10.1111/j.1572-0241.2002.05991.x.

    Article  PubMed  CAS  Google Scholar 

  24. Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn’s disease with infliximab alone or as an adjunct to examine under anaesthesia with seton placement. Inflamm Bowel Dis. 2003;9:98–103. doi:10.1097/00054725-200303000-00003.

    Article  PubMed  Google Scholar 

  25. Rasul I, Wilson SR, MacRae H, Irwin S, Greenberg GR. Clinical and radiological responses after infliximab treatment for perianal fistulising Crohn’s disease. Am J Gastroenterol. 2004;99:82–88. doi:10.1046/j.1572-0241.2003.04009.x.

    Article  PubMed  CAS  Google Scholar 

  26. Bell SJ, Halligan AC, Windsor ACJ, Williams AB, Wiesel P, Kamm MA. Response of fistulating Crohn’s disease to infliximab treatment assessed by magnetic resonance. Aliment Pharmacol Ther. 2003;17:387–393. doi:10.1046/j.1365-2036.2003.01427.x.

    Article  PubMed  CAS  Google Scholar 

  27. Schwartz DA, White CM, Wise PE, Herline AJ. Use of endoscopic ultrasound to guide combination medical and surgical therapy for patients with Crohn’s perianal fistulas. Inflamm Bowel Dis. 2005;11:727–732. doi:10.1097/01.MIB.0000172811.57242.18.

    Article  PubMed  Google Scholar 

  28. Rutgeerts P, Diamonds RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest Endosc. 2006;63:433–442. doi:10.1016/j.gie.2005.08.011.

    Article  PubMed  Google Scholar 

  29. Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut. 2007;56:453–455. doi:10.1136/gut.2005.088732.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology and Hepatology, ADEN EA 4311, Rouen University Hospital C Nicolle, 1 rue de Germont, 76031, Rouen, France

    David Tougeron, Guillaume Savoye & Eric Lerebours

  2. Radiology Department, Rouen University Hospital C Nicolle, 1 rue de Germont, 76031, Rouen, France

    Céline Savoye-Collet & Edith Koning

  3. Department of Surgery, Rouen University Hospital C Nicolle, 1 rue de Germont, 76031, Rouen, France

    Francis Michot

Authors
  1. David Tougeron
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guillaume Savoye
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Céline Savoye-Collet
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Edith Koning
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Francis Michot
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eric Lerebours
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guillaume Savoye.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tougeron, D., Savoye, G., Savoye-Collet, C. et al. Predicting Factors of Fistula Healing and Clinical Remission After Infliximab-Based Combined Therapy for Perianal Fistulizing Crohn’s Disease. Dig Dis Sci 54, 1746–1752 (2009). https://doi.org/10.1007/s10620-008-0545-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-008-0545-y

Keywords

Search

Navigation